New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

Table 1 Vorinostat in single agent trials

HDACI	Disease	Dose & schedule	Phase	No. Pts	Outcome	Reference
Vorinostat	Various cancer	400 mg, oral	I	476	Tolerated, safe	[21]
Vorinostat	CTCL	200 mg Bid PO	IIb	74	CR: 16% PR: 67% SD: 16%	[20]
Vorinostat	GI cancer	300 mg Bid PO 3 days/w q21d	II	16	safe, PK results	[26]
Vorinostat	TCC	200 mg Bid PO	II	14	study closed	[36]
Vorinostat	Breast, colon, lung Cancer	200–400 mg Bid PO ×14q21d	II	16	SD: 50%	[22]
Vorinostat	MM	200–300 mg Bid PO × 5d/wq28d/200–400 mg Bid PO × 14d/wq21d	I	13	No response	[40]
Vorinostat	DLBCL	300 mg Bid PO 3 days/week	II	18	CR: 5.5% SD: 5.5%	[23]
Vorinostat	Gynecologic tumor	400 mg/d PO	II	27	Insufficient activity (PR: 3%)	[37]
Vorinostat	MDS, leukemia	100–300 mg Bid/TidPO ×14q21d	1	41	MTD:200 mg Bid	[24]
Vorinostat	Head neck cancer	400 mg qd PO	II	12	No response	[41]
Vorinostat	mesothelioma	NR	I	13	PR: 15%	[35]

CR: complete responses; PR: partial response; SD: stable disease. MTD: maximal tolerated dose; NR: not reported.

ISSN: 1756-8722